

Robert S Kerbel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5274582/publications.pdf>

Version: 2024-02-01

169
papers

26,917
citations

13827

67
h-index

7718

150
g-index

173
all docs

173
docs citations

173
times ranked

25432
citing authors

#	ARTICLE	IF	CITATIONS
1	On coalescent angiogenesis and the remarkable flexibility of blood vessels. <i>Angiogenesis</i> , 2022, 25, 1-3.	3.7	5
2	Tumors resurrect an embryonic vascular program to escape immunity. <i>Science Immunology</i> , 2022, 7, eabm6388.	5.6	27
3	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e08253.	3.3	18
4	Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma. <i>Lancet, The</i> , 2021, 398, 278-279.	6.3	5
5	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , 2020, 39, 187-203.	2.6	34
6	Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 29.	2.3	26
7	Dr. Isaiah "Josh" Fidler, 1936-2020: A Fond Remembrance. <i>Neoplasia</i> , 2020, 22, 604-605.	2.3	0
8	Metronomic chemotherapy offsets HIF1 α induction upon maximum-tolerated dose in metastatic cancers. <i>EMBO Molecular Medicine</i> , 2020, 12, e11416.	3.3	20
9	A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. <i>EMBO Molecular Medicine</i> , 2020, 12, e12355.	3.3	7
10	Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity. <i>Angiogenesis</i> , 2019, 22, 535-546.	3.7	3
11	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. <i>PLoS ONE</i> , 2019, 14, e0222580.	1.1	7
12	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
13	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 16.	3.5	27
14	Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. <i>British Journal of Cancer</i> , 2019, 120, 196-206.	2.9	27
15	Title is missing!. , 2019, 14, e0222580.		0
16	Title is missing!. , 2019, 14, e0222580.		0
17	Title is missing!. , 2019, 14, e0222580.		0
18	Title is missing!. , 2019, 14, e0222580.		0

#	ARTICLE	IF	CITATIONS
19	Non-angiogenic tumours and their influence on cancer biology. <i>Nature Reviews Cancer</i> , 2018, 18, 323-336.	12.8	113
20	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 869-882.	1.9	20
21	Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 310-324.	12.5	412
22	Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1602-1612.	1.9	6
23	Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. <i>PLoS ONE</i> , 2018, 13, e0196892.	1.1	5
24	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	3.7	429
25	Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. <i>Angiogenesis</i> , 2018, 21, 793-804.	3.7	5
26	Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. <i>Scientific Reports</i> , 2018, 8, 9013.	1.6	27
27	The potential clinical promise of "multimodality" metronomic chemotherapy revealed by preclinical studies of metastatic disease. <i>Cancer Letters</i> , 2017, 400, 293-304.	3.2	59
28	A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. <i>Cancer Cell</i> , 2017, 31, 469-471.	7.7	7
29	Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. <i>Trends in Cancer</i> , 2017, 3, 529-541.	3.8	84
30	Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. <i>Molecular and Translational Medicine</i> , 2017, , 161-182.	0.4	0
31	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. <i>Journal of Pathology</i> , 2017, 241, 362-374.	2.1	162
32	Therapy-activated stromal cells can dictate tumor fate. <i>Journal of Experimental Medicine</i> , 2016, 213, 2831-2833.	4.2	10
33	Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. <i>Scientific Reports</i> , 2016, 6, 36694.	1.6	15
34	Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 659-673.	12.5	154
35	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw030.	3.0	144
36	Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. <i>Cancer Research</i> , 2016, 76, 6988-7000.	0.4	45

#	ARTICLE	IF	CITATIONS
37	Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. <i>Cancer Research</i> , 2016, 76, 5983-5993.	0.4	46
38	Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 97.	4.9	23
39	Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 4493-4503.	0.4	55
40	Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. <i>Neuro-Oncology</i> , 2016, 18, 974-981.	0.6	100
41	Exploiting drug repositioning and the brain microenvironment to treat brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 459-461.	0.6	0
42	Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , 2016, 388, 518-529.	6.3	663
43	Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. <i>PLoS ONE</i> , 2016, 11, e0158034.	1.1	21
44	Metronomic chemotherapy for triple negative breast cancer?. <i>Aging</i> , 2016, 8, 573-574.	1.4	5
45	Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. <i>EMBO Molecular Medicine</i> , 2015, 7, 770-787.	3.3	30
46	Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2015, 20, 1351-1352.	1.9	16
47	Lessons from the first e cancer symposium on angiogenesis in gastric cancer. <i>Ecancermedalscience</i> , 2015, 9, 553.	0.6	0
48	Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 42396-42410.	0.8	51
49	Rationale for metronomic chemotherapy in phase III trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 313-314.	12.5	25
50	A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 274-283.	1.0	56
51	PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 2138-2147.	3.2	71
52	Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5488-5498.	3.2	24
53	Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 2510-2519.	0.4	72
54	Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 808-818.	3.2	70

#	ARTICLE	IF	CITATIONS
55	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <i>Science Translational Medicine</i> , 2015, 7, 282ra50.	5.8	48
56	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
57	Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. <i>EMBO Molecular Medicine</i> , 2014, 6, 1561-1576.	3.3	36
58	Lenalidomide and metronomic melphalan for CMML and higher risk MDS: A phase 2 clinical study with biomarkers of angiogenesis. <i>Leukemia Research</i> , 2014, 38, 756-763.	0.4	20
59	Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. <i>Angiogenesis</i> , 2014, 17, 129-146.	3.7	22
60	Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. <i>Angiogenesis</i> , 2014, 17, 661-73.	3.7	19
61	Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. <i>Angiogenesis</i> , 2014, 17, 641-659.	3.7	31
62	Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective. , 2014, , 3-21.		2
63	Drug rechallenge and treatment beyond progressionâ€™ implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 571-587.	12.5	219
64	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1465-E1473.	1.8	33
65	Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors. <i>Cancer Research</i> , 2013, 73, 1892-1899.	0.4	160
66	Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis. <i>Breast</i> , 2013, 22, S57-S65.	0.9	38
67	Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. <i>Gut</i> , 2013, 62, 259-271.	6.1	98
68	Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2013, 6, 511-519.	1.7	42
69	A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs. <i>Cancer Research</i> , 2013, 73, 2743-2748.	0.4	84
70	Differential Post-Surgical Metastasis and Survival in SCID, NOD-SCID and NOD-SCID-IL-2RÎ³null Mice with Parental and Subline Variants of Human Breast Cancer: Implications for Host Defense Mechanisms Regulating Metastasis. <i>PLoS ONE</i> , 2013, 8, e71270.	1.1	35
71	Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 680-689.	1.9	38
72	Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 229-239.	1.0	34

#	ARTICLE	IF	CITATIONS
73	Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 673-688.	3.4	97
74	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012, 15, 275-286.	3.7	61
75	Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor. <i>Clinical Cancer Research</i> , 2011, 17, 5656-5667.	3.2	79
76	Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma. <i>Neoplasia</i> , 2011, 13, 187-197.	2.3	30
77	Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 210-221.	12.5	600
78	Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide. <i>Neoplasia</i> , 2011, 13, 40-48.	2.3	57
79	G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. <i>Blood</i> , 2011, 118, 3426-3435.	0.6	58
80	Mouse models of advanced spontaneous metastasis for experimental therapeutics. <i>Nature Reviews Cancer</i> , 2011, 11, 135-141.	12.8	333
81	Reappraising antiangiogenic therapy for breast cancer. <i>Breast</i> , 2011, 20, S56-S60.	0.9	55
82	Forty-Year Journey of Angiogenesis Translational Research. <i>Science Translational Medicine</i> , 2011, 3, 114rv3.	5.8	181
83	Chemotherapy counteracted. <i>Nature</i> , 2010, 468, 637-638.	13.7	47
84	Raising the bar for cancer therapy models. <i>Nature Biotechnology</i> , 2010, 28, 561-562.	9.4	53
85	Peering into the aftermath: The inhospitable host?. <i>Nature Medicine</i> , 2010, 16, 1084-1085.	15.2	21
86	Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 996-1006.	1.9	102
87	Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2. <i>MAbs</i> , 2010, 2, 199-208.	2.6	57
88	Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy. <i>Neoplasia</i> , 2010, 12, 928-940.	2.3	64
89	Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma. <i>Neoplasia</i> , 2010, 12, 264-274.	2.3	46
90	Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action. , 2010, , 117-134.		1

#	ARTICLE	IF	CITATIONS
91	Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer. <i>Recent Results in Cancer Research</i> , 2010, 180, 165-183.	1.8	29
92	Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy. , 2010, , 257-273.		0
93	Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1. <i>Cancer Research</i> , 2009, 69, 7243-7251.	0.4	331
94	A role for the TGF β -Par6 polarity pathway in breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14028-14033.	3.3	115
95	Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2872-2881.	1.9	83
96	Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens. <i>Clinical Cancer Research</i> , 2009, 15, 4867-4874.	3.2	32
97	Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2 α -Positive Human Breast Cancer Xenografts. <i>Clinical Cancer Research</i> , 2009, 15, 6358-6366.	3.2	43
98	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. <i>Cancer Research</i> , 2009, 69, 7524-7528.	0.4	78
99	Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5020-5025.	3.2	258
100	Tumor-Associated Fibroblasts as "Trojan Horse" Mediators of Resistance to Anti-VEGF Therapy. <i>Cancer Cell</i> , 2009, 15, 3-5.	7.7	45
101	Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. <i>Cancer Cell</i> , 2009, 15, 232-239.	7.7	1,624
102	Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. <i>Breast</i> , 2009, 18, S41-S47.	0.9	33
103	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. <i>Cancer Cell</i> , 2008, 14, 263-273.	7.7	424
104	Tumor Angiogenesis and the Cancer Stem Cell Model. , 2008, , 249-258.		1
105	Tumor Angiogenesis. <i>New England Journal of Medicine</i> , 2008, 358, 2039-2049.	13.9	1,996
106	Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using 125 I-human choriogonadotropin secreting tumor cell lines. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3452-3459.	1.9	31
107	Development of a Preclinical Model of Spontaneous Human Melanoma Central Nervous System Metastasis. <i>Cancer Research</i> , 2008, 68, 4500-4505.	0.4	121
108	Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease. , 2008, , 63-80.		1

#	ARTICLE	IF	CITATIONS
109	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. Blood, 2008, 112, 1885-1885.	0.6	0
110	Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy: Figure 1.. Cancer Research, 2007, 67, 7055-7058.	0.4	109
111	Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and Perspectives. Oncology Research and Treatment, 2007, 30, 606-608.	0.8	23
112	Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Molecular Cancer Therapeutics, 2007, 6, 2280-2289.	1.9	47
113	Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors. Cancer Research, 2007, 67, 3560-3564.	0.4	373
114	Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity. Journal of Clinical Oncology, 2007, 25, 1816-1818.	0.8	56
115	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17069-17074.	3.3	360
116	Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis. Molecular Imaging, 2007, 6, 7290.2007.00024.	0.7	105
117	Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs. Cancer Research and Treatment, 2007, 39, 150.	1.3	42
118	Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discovery Today, 2007, 12, 806-812.	3.2	84
119	On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer and Metastasis Reviews, 2007, 26, 737-747.	2.7	41
120	Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?. Science, 2006, 312, 1171-1175.	6.0	444
121	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 2006, 108, 452-459.	0.6	242
122	The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Reviews Cancer, 2006, 6, 835-845.	12.8	559
123	Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy. Cancer Research, 2006, 66, 3386-3391.	0.4	218
124	Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts. Clinical Cancer Research, 2006, 12, 904-916.	3.2	140
125	Targeted Anti-vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia. Cancer Research, 2006, 66, 3639-3648.	0.4	150
126	Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clinical Cancer Research, 2006, 12, 4331-4338.	3.2	67

#	ARTICLE	IF	CITATIONS
127	High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 5190-5198.	3.2	106
128	Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors. <i>Science</i> , 2006, 313, 1785-1787.	6.0	543
129	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. <i>Blood</i> , 2005, 106, 3058-3061.	0.6	252
130	Angiogenesis as a therapeutic target. <i>Nature</i> , 2005, 438, 967-974.	13.7	2,384
131	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis. <i>Cancer Cell</i> , 2005, 7, 101-111.	7.7	332
132	Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. <i>Cancer Cell</i> , 2005, 8, 269-271.	7.7	59
133	Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1484-1494.	1.9	33
134	In vitro Procoagulant Activity Induced in Endothelial Cells by Chemotherapy and Antiangiogenic Drug Combinations: Modulation by Lower-Dose Chemotherapy. <i>Cancer Research</i> , 2005, 65, 5365-5373.	0.4	73
135	Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy. <i>Cancer Research</i> , 2005, 65, 7045-7051.	0.4	134
136	A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens. <i>Cancer Research</i> , 2004, 64, 3994-4000.	0.4	129
137	Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies. <i>Cancer Research</i> , 2004, 64, 6616-6625.	0.4	158
138	The anti-angiogenic basis of metronomic chemotherapy. <i>Nature Reviews Cancer</i> , 2004, 4, 423-436.	12.8	1,302
139	Antiangiogenic drugs and current strategies for the treatment of lung cancer. <i>Seminars in Oncology</i> , 2004, 31, 54-60.	0.8	28
140	A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma. <i>Molecular Cancer Research</i> , 2004, 2, 315-326.	1.5	163
141	Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. <i>European Journal of Pharmacology</i> , 2003, 477, 17-21.	1.7	5
142	Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. <i>Cancer</i> , 2003, 98, 1643-1648.	2.0	155
143	Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived "But They Can Be Improved. <i>Cancer Biology and Therapy</i> , 2003, 2, 133-138.	1.5	186
144	Some Guidelines to Building a Successful Laboratory and Career in Cancer Research. <i>Cancer Biology and Therapy</i> , 2003, 2, 112-115.	1.5	2

#	ARTICLE	IF	CITATIONS
145	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. <i>Cancer Research</i> , 2003, 63, 4342-6.	0.4	375
146	Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. <i>Cancer Biology and Therapy</i> , 2003, 2, S134-9.	1.5	179
147	A role for survivin in chemoresistance of endothelial cells mediated by VEGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 4349-4354.	3.3	414
148	Effect of p53 Status on Tumor Response to Antiangiogenic Therapy. <i>Science</i> , 2002, 295, 1526-1528.	6.0	419
149	Reply to "Limitations of combination anti-angiogenesis and chemotherapy". <i>Nature Reviews Cancer</i> , 2002, 2, 804-804.	12.8	0
150	Clinical translation of angiogenesis inhibitors. <i>Nature Reviews Cancer</i> , 2002, 2, 727-739.	12.8	1,432
151	Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. <i>Cancer Research</i> , 2002, 62, 2731-5.	0.4	244
152	Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. <i>Cancer Research</i> , 2002, 62, 6938-43.	0.4	330
153	Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. <i>Cancer and Metastasis Reviews</i> , 2001, 20, 79-86.	2.7	218
154	Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. <i>Oncogene</i> , 2000, 19, 395-402.	2.6	50
155	Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. <i>Oncogene</i> , 2000, 19, 4611-4620.	2.6	189
156	Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. <i>Journal of Clinical Investigation</i> , 2000, 105, R15-R24.	3.9	1,010
157	Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. <i>Oncogene</i> , 1999, 18, 1023-1032.	2.6	71
158	Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. , 1999, 81, 118-124.		98
159	The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. <i>Angiogenesis</i> , 1998, 2, 203-217.	3.7	26
160	What is the optimal rodent model for anti-tumor drug testing?. , 1998, 17, 301-304.		60
161	Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma. , 1997, 74, 464-469.		155
162	Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma. <i>International Journal of Cancer</i> , 1997, 74, 464-469.	2.3	7

#	ARTICLE	IF	CITATIONS
163	Commentaries on tumor angiogenesis: an introduction. <i>Cancer and Metastasis Reviews</i> , 1996, 15, 145-147.	2.7	3
164	Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. <i>Nature Medicine</i> , 1996, 2, 1204-1210.	15.2	291
165	Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. <i>Journal of Cellular Physiology</i> , 1994, 159, 245-255.	2.0	54
166	Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. <i>International Journal of Cancer</i> , 1991, 48, 557-561.	2.3	11
167	Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. <i>International Journal of Cancer</i> , 1991, 49, 938-939.	2.3	64
168	Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. <i>BioEssays</i> , 1991, 13, 31-36.	1.2	423
169	Metronomic Chemotherapy for Treatment of Metastatic Disease: From Preclinical Research to Clinical Trials. , 0, , 573-586.		2